Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
This study examines the long-term effects of interleukin-2 (IL-2) in combination with
anti-HIV drugs, or highly active antiretroviral therapy (HAART). The purpose of this study is
to see if IL-2 can increase the number of CD4 cells (cells of the immune system which fight
infection) in HIV-infected patients who have completed ACTG 328.
HAART is often successful in decreasing viral load (level of HIV in the blood), but these
drugs have not been able to restore the immune systems of HIV-infected patients. IL-2 is a
substance naturally produced by the body's immune cells. In ACTG 328, IL-2 is tested to see
if it can increase the number of CD4 cells and "boost" a patient's immune system. This study
is a follow-up to ACTG 328 so that patients who are benefiting from IL-2 can continue to take
it and patients in the control group who do not receive IL-2 can start taking it.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)